CD70 and primary cutaneous T-cell non-Hodgkin lymphoma: Clinical trials utilizing the blockade of CD70 in CTCL have been carried out with a recent phase I trial showing that the treatment is safe, well-tolerated, and resulted in a 23% overall response rate, with some patients regressing from plaque to patch stage after treatment [80].